The estimated Net Worth of Amato Giaccia is at least $161 ezer dollars as of 30 November 2021. Amato Giaccia owns over 51,611 units of Aravive Inc stock worth over $39,740 and over the last 6 years he sold ARAV stock worth over $0. In addition, he makes $120,929 as Independent Director at Aravive Inc.
Amato has made over 2 trades of the Aravive Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 51,611 units of ARAV stock worth $10,322 on 30 November 2021.
The largest trade he's ever made was exercising 51,611 units of Aravive Inc stock on 30 November 2021 worth over $10,322. On average, Amato trades about 7,077 units every 28 days since 2019. As of 30 November 2021 he still owns at least 993,491 units of Aravive Inc stock.
You can see the complete history of Amato Giaccia stock trades at the bottom of the page.
Dr. Amato Giaccia Ph.D. serves as Independent Director of the Company. Prior to the closing date of the Merger, he also served as a member of the board of directors of Private Aravive from August 2010 to October 2018 and as Acting Chief Scientific Officer of Private Aravive from January 2017 until the Merger was completed on October 12, 2018. Dr. Giaccia also served as Professor of Radiation Oncology, Associate Chair for Research & Director of the Division of Radiation & Cancer Biology in the Department of Radiation Oncology at Stanford University School of Medicine, a position he has held since 2011 and has been a Director of Oxford Institute of Radiation Oncology since January 2019. He is also the Associate Director for Basic Science and leader of the Radiation Biology Program in Stanford Cancer Institute. He has also served as the Director of the Cancer Biology Interdisciplinary Graduate Program and is currently the “Jack, Lulu and Sam Willson Professor in Cancer Biology” in the Stanford University School of Medicine. Dr. Giaccia received his Ph.D. from the University of Pennsylvania.
As the Independent Director of Aravive Inc, the total compensation of Amato Giaccia at Aravive Inc is $120,929. There are 4 executives at Aravive Inc getting paid more, with Gail McIntyre having the highest compensation of $713,495.
Amato Giaccia is 61, he's been the Independent Director of Aravive Inc since 2018. There are 2 older and 8 younger executives at Aravive Inc. The oldest executive at Aravive Inc is Fredric Eshelman, 72, who is the Independent Chairman of the Board.
Amato's mailing address filed with the SEC is C/O ARAVIVE, INC., RIVER OAKS TOWER,, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX, 77098.
Over the last 6 years, insiders at Aravive Inc have traded over $107,045 worth of Aravive Inc stock and bought 151,333 units worth $1,102,898 . The most active insiders traders include Srinivas Akkaraju, Fredric N Eshelman Ventures... és Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of $11,962. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth $181,818.
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
Aravive Inc executives and other stock owners filed with the SEC include: